Last reviewed · How we verify
Fluad
At a glance
| Generic name | Fluad |
|---|---|
| Also known as | Adjuvanted influenza vaccine, standard-dose, inactivated influenza (flu) vaccine, Adjuvanted Trivalent, inactivated influenza vaccine, adjuvanted influenza vaccine |
| Sponsor | University of Surrey |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
- Open-Label Influenza Vaccine Evaluation (NA)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults (PHASE4)
- Systems Investigation of Vaccine Responses in Aging and Frailty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |